Xbrane Drops Keytruda Rival As It Pares Down Pipeline And Personnel
Swedish Biosimilars Developer Discloses ‘Unfortunately Necessary Measures’ To Cut Costs
Executive Summary
Swedish biosimilars developer Xbrane Biopharma has revealed that it is dropping development of its planned Xtrudane pembrolizumab biosimilar to Keytruda, as part of a move towards a more “focused development portfolio.” At the same time, the firm has announced job cuts as part of a new cost-savings scheme designed to help the firm “achieve a positive cash flow as soon as possible.”